Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.
The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.
The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.
Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.
The firm expects to use proceeds from the offering to expand its life sciences commercial operations, and improve and update its Simoa technology and instruments, among other initiatives.
The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.
NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.
The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.
The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
The company expects the rollout of more reliable, user-friendly platforms will increase instrument usage among a substantial segment of its customer base.
The Gaithersburg, Maryland-based company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.
LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
The system has been evaluated by researchers studying cervical cancer prevention as well as other HPV-related cancers, with positive feedback so far.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
In an earnings call, the firm said it sees growth continuing for the BD Max, BD Cor, and Phoenix systems, and in China in general.
The firm received a notice from Nasdaq on August 2 saying its stock had not met the $1-per-share closing bid price requirement for 30 consecutive business days.
The national project has developed infrastructure for implementing genomics into clinical care and is now studying clinical utility and cost effectiveness.
The company attributed the revenue decline to a 96 percent drop in licensing revenues, which more than offset a 36 percent increase in product sales.